Protagenic Therapeutics, Inc. - Common Stock (PTIX)
0.7400
+0.00 (0.00%)
NASDAQ· Last Trade: Jul 1st, 1:21 AM EDT
Detailed Quote
Previous Close
0.7400
Open
-
Bid
0.4400
Ask
0.4999
Day's Range
N/A - N/A
52 Week Range
0.7400 - 6.200
Volume
0
Market Cap
1.34M
PE Ratio (TTM)
-0.2145
EPS (TTM)
-3.5
Dividend & Yield
N/A (N/A)
1 Month Average Volume
-
Chart
About Protagenic Therapeutics, Inc. - Common Stock (PTIX)
Protagenic Therapeutics Inc is a biotechnology company focused on the development of innovative therapies for neurological and psychiatric disorders. The company leverages its proprietary technologies to identify and develop peptides that target specific neuronal pathways, with the aim of addressing unmet medical needs in conditions such as depression and anxiety. Through its research and development efforts, Protagenic Therapeutics seeks to create effective treatment options that can enhance the quality of life for patients suffering from these complex disorders. Read More
As published in Behavioural Pharmacology, two days of PT00114 treatment reduced corticosterone levels and attenuated anxiety-like behavior in chronically stressed rats; a known CRF₁ receptor antagonist did not show activity in the same model.
NEW YORK, NY / ACCESS Newswire / May 19, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company developing novel peptide-based therapies for stress-related neuropsychiatric disorders, today announced two strategic engagements to support the advancement of its lead candidate, PT00114. The Company has engaged Floyd Regulatory Strategic Consulting, led by regulatory affairs veteran Dr. Eric Floyd, Ph.D., MBA, as Regulatory Affairs Advisor, and DanforthHealth, a premier life science operational consulting firm, to establish institutional-grade operational processes and infrastructure. Together, these engagements reflect Protagenic's deliberate, lean operating model concentrating resources and expertise on PT00114's Phase 2 advancement while positioning the Company for long-term value creation for patients and shareholders.
NEW YORK, NY / ACCESS Newswire / April 23, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company pioneering first-in-class neuropeptide therapies for stress-related neuropsychiatric disorders, today announced the appointment of Bill Nichols Jr. as President. This strategic leadership addition, combined with a thoughtful optimization of the Company's management structure, sharpens focus and resources on advancing its lead candidate, PT00114 - positioning Protagenic for accelerated clinical progress and long-term value creation for patients and shareholders alike.
Returned and cancelled merger shares, removal of more than $6.3 million of liabilities and over $1 million of annualized cost savings position Protagenic as a leaner company centered on PT00114
NEW YORK CITY, NY / ACCESS Newswire / November 13, 2025 / Protagenic Therapeutics Inc. (NASDAQ:PTIX), a biopharmaceutical company developing novel therapeutics for stress-related neuropsychiatric and neurodegenerative disorders, today announced the successful completion of enrollment and dosing in its Multiple Ascending Dose (MAD) Phase 1 study evaluating its lead compound, known as PT00114. The study, conducted in healthy volunteers, was designed to assess the safety and tolerability profile of PT00114 following multiple doses over time. With all healthy volunteers now dosed, the company has achieved a milestone in the clinical development of its proprietary peptide-based therapeutic.
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Shares of Protagenic Therapeutics are trading sharply higher Thursday afternoon. The stock soared over 100% midday after the company announced a key clinical milestone.
As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
